Arcutis Biotherapeutics Inc(ARQT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 112.89 | EPS (ttm) | 0.21 | Insider Own | 12.95% | Shs Outstand | 125.6M | Perf Week | -1.97% |
| Market Cap | 2.94B | Forward P/E | 18.16 | EPS next Y | 171.05% | Insider Trans | -0.69% | Shs Float | 109.4M | Perf Month | -10.87% |
| Enterprise Value | 2.81B | PEG | - | EPS next Q | 0.17 | Inst Own | 96.06% | Short Float | 13.45% | Perf Quarter | 0.65% |
| Income | 0.03B | P/S | 6.33 | EPS this Y | 465.38% | Inst Trans | -0.97% | Short Ratio | 8.46 | Perf Half Y | -2.38% |
| Sales | 0.46B | P/B | 13.31 | EPS next 5Y | - | ROA | 6.78% | Short Interest | 14.72M | Perf YTD | -19.49% |
| Book/sh | 1.76 | P/C | 12.3 | EPS past 3/5Y | 71.8% 49.34% | ROE | 15.86% | 52W High | -26.41% ($31.77) | Perf Year | 33.07% |
| Cash/sh | 1.9 | P/FCF | 75.06 | Sales past 3/5Y | 367.27% - | ROIC | 8.7% | 52W Low | 41.1% ($16.57) | Perf 3Y | 215.09% |
| Dividend Est. | - | EV/EBITDA | 75.64 | EPS Y/Y TTM | 129.74% | Gross Margin | 91.14% | Volatility(W/M) | 3.57% 3.7% | Perf 5Y | 10.54% |
| Dividend TTM | - | EV/Sales | 6.06 | Sales Y/Y TTM | 76.11% | Oper. Margin | 7.38% | ATR (14) | 0.95 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.67 | EPS Q/Q | 188.25% | Profit Margin | 6.15% | RSI (14) | 36.34 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.92 | Sales Q/Q | 59.33% | SMA20 | -5.58% ($24.76) | Beta | 1.59 | Target Price | $36.88 |
| Payout | - | Debt/Eq | 0.52 | Earnings | 2026/8/5 | SMA50 | -10.77% ($26.2) | Rel Volume | 1.02 | Prev Close | $23.84 |
| Employees | 354 | LT Debt/Eq | 0.49 | EPS/Sales Surpr. | 99.64% 9.26% | SMA200 | -8.49% ($25.55) | Avg Volume(3M) | 1.74M | Price | $23.38 |
| IPO | 2020/1/31 | Option/Short | Yes/Yes | Trades | 16041 | Volume | 1,782,377 | Change | -1.93% |
Company
ARQT is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A U.S. biotech company that develops and commercializes treatments for skin diseases. It focuses on developing and commercializing therapies for skin conditions such as psoriasis and eczema, and is gaining attention as it advances the commercialization of new drugs and expands prescriptions. The company is a biotech firm specialized in treatments for skin diseases.
Over the past 1 year, roughly in the middle
26% below its 1-year high.
ARQT makes money exceptionally well
7.38% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +465.4% this year.
Tap to view numbers
But it is not cheap
Trading at 112.9 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +215.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 96.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BBP 0.01%
GURU 0.01%
LABU 0.01%
XBI 0.01%
XEUR 0.01%It ranks #4 in the industry
Based on market cap of $3B.
ARQT $3B PER 112.9
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is ARQT?
ARQT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ARQT?
The market cap of ARQT is approximately $2.9B, ranking 1,789 within its sector.
What is the P/E ratio of ARQT?
ARQT has a P/E ratio of approximately 112.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ARQT?
ARQT has recorded a 52-week high of $31.77 and a low of $16.57.
